SSRI China news

News archive


March: Pfizer, AstraZeneca and Bayer are the top 3 companies for sales rep visitations

According to PatientsMap CN 2019 data which asks doctors about sales reps that have visited them in the past month for 64 pharmaceutical companies, approximately 1/3 of the 12,000 physicians in China have answered that they met a sales rep from Pfizer and AstraZeneca in the past month.  Below table shows the top 10 pharmaceutical companies with the highest sales rep visitation rates overall.

Compared to 2018 data, while the top 4 companies remain unchanged, we see more domestic pharma companies in the top 10 (2 companies in 2018 vs. 4 companies in 2019), and CTTQ pharmaceutical moved from 8th to 5th.  In particular for the oncology area, there are 5 domestic pharma companies in the top 10 sales rep visits, with the top being a domestic company Hengrui with 50.2% sales rep visitation rate. This may suggest that the domestic companies are starting to enhance their sales force activities.

The highest ranked Japanese companies were Eisai (25th with 7.2%), Takeda (27th with 5.3%) and Daiichi Sankyo (29th with 4.9%).


For more information about PatientsMap CN 2019, please see below:

March: Launch of PatientsMap China 2019

On March 3rd, 2020, SSRI and M3 launched the updated version of PatientsMap China


Introduction to PatientsMap:

PatientsMap is a database product which uncovers the types of diseases that various specialists see, and the monthly patient volume for each disease. The data is collected from around 40,000 physicians (from Japan, USA, UK and China) covering approximately 400 diseases/conditions.  PatientsMap data collection is conducted via online in collaboration with M3.

PatientsMap can also be used as a tool for estimating nationwide patient numbers for various diseases across, not only different specialties, but also by hospital tiers and city tiers. It can help you in analyzing the potential of a new drug and also for targeting the appropriate specialties in terms of market research and/or for promotional purposes.

PatientsMap China 2019 data was collected from over 12,000 physicians (approx. 20% increase from 2018 version), covering approximately 380 diseases/conditions.

Outline of PatientsMap 2019 China:

  1. Product name: PatientsMap 2019 China
  2. Objective: To understand the treatment condition of various specialties for 357 diseases/conditions
  3. Methodology: Online survey
  4. Survey region: Nationwide
  5. Sample size: 12,108 physicians from various departments
  6. Fieldwork schedule: 2019 September 6th – December 5th

Contents of PatientsMap:

  • > Total number of patients that they see (per month)
  • > Diseases/conditions that they see (386 disease types)
  • > Number of patients they see per each disease/condition
  • > Number of patients in which they prescribe medications for that disease/condition
  • > Diseases in which they wish for new product development
  • > Sales rep visitations in the past month (64 manufacturers)
  • > Information provision via non-face-to-face methods (64 manufacturers)
  • > Demographics
  •      - Primary specialty
  •      - Area of specialty/sub-specialties
  •      - Province and city of the practice
  •      - Hospital type and tier level
  •      - Number of beds at the hospital
  •      - Title
  •      - Age range

For more information on PatientsMap, please contact;


November: SSRI CHINA @ CphMRA 2019 conference


Staffs from SSRI CHINA and SSRI headquarters attended the 8th CphMRA (China Pharmaceutical Market Research Association) conference held during October 23rd-25th in Nanjing. There was an attendance of around 300 people, and according to the organizers, around 2/3 of the attendees were from pharmaceutical companies. SSRI CHINA had a booth, participated in a poster session, and Jane Zhang did a presentation about diseases with high unmet needs in China based on the PatientsMap CN 2018 data.



Jane’s presentation explained that hypertension, diabetes, hyperlipidemia and COPD are the top diseases in which Chinese physicians wish for new treatments overall, suggesting that lifestyle diseases are considered as a major social problem in China.  However, when looking at more specific conditions that are treated by more specialized doctors, hematologic malignancies, neuro-muscular disorders and psychiatric conditions are considered as diseases with very high unmet needs, suggesting that for specific conditions, there is a high unmet need for innovative and/or orphan drugs, which is similar to that of Western countries.  Jane’s presentation received a third-place award out of all 33 presentations.



About PatientsMap

PatientsMap is a physician survey database product which uncovers the types of diseases that various specialists see, and the monthly patient volume for each disease. The database product is available for 4 countries; Japan, USA, UK and China. PatientsMap China 2018 data is collected from over 10,000 physicians, covering approximately 350 diseases/conditions.

For more details, please refer to the PatientsMap page in our website (above tab); /china/e/patientsmap

May: Intellus 2019

SSRI and SSRI CHINA attended the Intellus Worldwide Summit in Philadelphia from May 19-21. We had a booth (as always) and we had many gifts (as always). Those macaron shaped post it notes look nice...


Chiharu from HQ and Jane from CN

May: PatientsMap 2018 CN - Sales rep visitation rate by clinical departments

Previously (in July 2018), we shared the top 15 pharmaceutical companies with the highest sales rep visitation rates in China according to the PatientsMap 2018 CN data (table 2).


This time, we are sharing the top 5 pharmaceutical companies with the highest sales rep visitation rates in specific clinical departments, in particular, clinical departments with relatively strong domestic company presence.


Table 1 shows the top 5 companies with highest sales rep visitation rates in 10 clinical departments (e.g. 48.7% of 476 gastroenterologists met a sales rep from AstraZeneca in the past month). While major global companies generally occupy the top 3 spots, there are also some domestic companies such as Chia-Tai Tianqing (CTTQ) Pharmaceutical and Jiangsu Hengrui Medicine that rank highly in some clinical departments. In particular, domestic companies occupy the top 3 stops in the anesthesiology department.

In terms of domestic companies, Hengrui ranks second in radiology and anesthesiology departments and third in RA/immunology and oncology departments; and CTTQ ranks second in gastroenterology and infectious diseases departments and third in hematology department.


The rankings for all 32 clinical departments are available in the PatientsMap 2018 CN database.


Table 1. Top 5 sales rep visits (10 departments)


Table 2. PatientsMap 2018 CN – top 15 sales rep visits (n=10,285) from July 2018 news release


See more
Page Top